

## Feraheme - (EQ 510MG IRON/17ML; Solution, Intravenous)

|                              |                                                                                                            |                             |                     |
|------------------------------|------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|
| <b>Generic Name</b>          | Ferumoxytol                                                                                                | <b>Innovator</b>            | Amag Pharma         |
| <b>Dosage</b>                | EQ 510MG IRON/17ML; Solution, Intravenous                                                                  | <b>Branded US Sales</b>     | Less Than \$1000 mn |
| <b>Probable FTF</b>          | Less Than 5                                                                                                | <b>Known Para IV Filers</b> | Less Than 5         |
| <b>Other ANDA developers</b> | More Than 5                                                                                                | <b>Tentative Approvals</b>  | None                |
| <b>Final Approvals</b>       | Less Than 5                                                                                                | <b>Generic Launches</b>     | Less Than 5         |
| <b>Indication</b>            | Indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD). |                             |                     |
| <b>Complexities</b>          | Yes                                                                                                        |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.